Fig. 3.

OA treatment protects from intestinal permeability and mucus alteration in EAE mice. a Serum levels of soluble CD14 and iFABP were quantified by ELISA. b Intestinal sacs prepared from colon to assess intestinal permeability. Sacs were loaded with FITC-labeled Dextran (FD-40) and placed in a bath. After 120 min, the FD-40 concentration from the bath solutions was quantified. c Expression of GDNF in colon tissue quantified by ELISA. d Histological analysis of colon mucins stained with Alcian Blue/Periodic acid-Schiff (AB/PAS). Objective lens × 10, × 20, and × 20, respectively. Representative photomicrographs (left), quantification graphs (right). e Expression of galectin-3 (Gal-3) in colon tissue quantified by ELISA. Results were expressed as the mean ± SEM, n = 5–7 per group. *p < 0.001 and **p < 0.01 vs control; and ^‡p < 0.001, ^‡‡p < 0.01, and ^‡‡‡p < 0.05 vs untreated-EAE. C, healthy mice. C + OA, healthy mice treated with OA. EAE, induced mice. EAE + OA, induced-mice treated with OA